Background
Introduction
Serum apolipoprotein A-II (ApoA-II) was found to be depressed in pancreatic cancer patients and was a potential diagnostic biomarker [1] . This work has been confirmed by Honda and colleagues [2] and others [3] . ApoA-II is a component of high density lipoprotein (HDL) where it has an important role in directing the fate of the metabolism of the lipid in the HDL. The most important role for HDL is the delivery of cholesterol from peripheral tissues to the liver where it is metabolised into bile salts or excreted to the bile. The scavenger receptor class B type-1 (SR-B1) is prevalent in hepatocytes and attracts HDL where the lipid is endocytosed [4, 5] or diffused [6, 7] in hepatocytes.
SR-B1 is a multi-ligand receptor and highly expressed in a variety of tumor cells including prostate, breast, colorectal and ovarian cancer cells [8] . The lipoprotein on the surface of HDL binds to SR-B1and delivers its lipid into the cell through a pore formed by SR-B1 increasing the uptake of HDL-cholesteryl ester (CE) [9] , an essential nutrient for malignant cell proliferation and metastasis [10, 11] . Thirty percent of HDL is associated with ApoA-II which is thought to make the HDL smaller than that with ApoA-I alone and makes the HDL/ApoA-II less attracted to the hepatic SR-B1 [12] . In addition, ApoA-II maintains HDL levels in part by inhibition of hepatic lipase [13] . These results in a relatively longer circulation time for HDL/ ApoA-II. ApoA-II alters binding of HDL to SR-B1 in different tissues and is particularly attracted to steroidogenic tissue [14] where the cholesterol is utilized for hormone synthesis but rapidly growing cancer cells also require cholesterol for cell membranes [15] . Cancer cells have an increased expression of SR-B1in relation to the expression on their non-malignant cells of origin [16, 17] and it is possible that this results in increased uptake of HDL by the cancer tissue which is an explanation for the reduction in serum ApoA-II in PDAC cases [1] [2] [3] . Interestingly pancreatic cancer does not accumulate fludeoxyglucose (FDG) strongly enough to be reliable as a contrast agent for Positron Emission Tomography (PET) [18] which probably indicates that pancreatic cancer has a preference for lipid as its main calorie source [19] . If lipid is the main source of energy for pancreatic cancer tissue it is possible that HDL is an important source of this lipid. Energy metabolism of the cells is involved in complex carcinogenesis [20, 21] . The role of cholesterol metabolism in the process of carcinogenesis is also reported [22] [23] [24] .Cancer and other rapidly proliferating cells require cholesterol and other membrane components to optimize growth [25] . HDLs have been implicated in cholesterol delivery in some malignancies, including breast cancer [26] , ovarian cancer [8] , adrenocortical tumours [27] and prostate cancer [28] . It is likely that pancreatic cancer is also avidly utilsing HDL.
The hypothesis tested in this paper is that ApoA-II will expedite the uptake of lipid into pancreatic cancer tissue and will thus increase cell growth. Further, we hypothesize that the level of expression of SR-B1 will correlate with the uptake of lipid by pancreatic cancer cells and will be greater than that of normal tissue.
Materials and Methods

Cell culture
PANC-1, MIAPaCa-2, BxPC3 and CFPAC-1 pancreatic cancer cell lines were gifts from Prof. Barry Allen (St George Hospital, NSW, Australia), and normal human pancreatic ductal epithelial (HPDE6) cells [29] were from Dr. Chris Scarlett (School of Environmental & Life Sciences, University of Newcastle, NSW, Australia). A549 lung cancer cell line, T47D and MCF7 breast cancer cell lines were kindly provided by Prof. Ross Davey (Kolling Institute of Medical Research, Royal North Shore Hospital, NSW, Australia). PC3 prostate cancer cell line was kindly provided by Prof. Qihan Dong (Central Clinical School, Bosch Institute, The University of Sydney, NSW, Australia). Except HPDE6 cell line, all cell lines were purchased from ATCC. Cell lines were typed by short tandem repeat profiling and they conformed to the ATCC reference standards (CellBank, Westmead, NSW, Australia). BxPC3, CFPAC-1, A549, T47D and MCF7 cell lines were cultured in RPMI 1640, PANC-1and MIAPaCa-2 were cultured in Dulbecco's Modified Eagle Medium (DMEM) and PC3 prostate cells were cultured in F-12K (Gibco, BRL) with 10% FBS, containing 10% fetal bovine serum (FBS; ICN, Aurora, OH) in 75 cm 2 flasks at 37°C in a humidified 5% CO 2 atmosphere. HPDE6 cells were cultured in keratinocyte serum-free (KSF) medium supplemented by epidermal growth factor and bovine pituitary extract (Life Technologies, Inc., Grand Island, NY).
Primary culture
Human pancreatic tumour specimens were obtained at the Royal North Shore Hospital (Sydney, Australia), with their informed written consent, following protocols approved by the Northern Sydney Local Health District Human Research Ethics Committee (NSLHD HREC) (Protocol number: 0909-227M, Sydney, Australia). Primary tumour cell cultures were established by explant growth of small fragments (%1 mm) dissected from the PDAC tumour tissues, placed in DMEM (pH7.4) supplemented with 10% heat-inactivated FBS with 50 units/ml penicillin/streptomycin. Cultures were used after passage 3 to avoid residual contamination by macrophages [30] . All cultures were collected under identical growth and serum conditions. We used 24 h serum starved cells for experiments to avoid the early gene expression induced by serum.
Labeling of SMOF lipid with the fluorophore DiD
The SMOF lipid emulsion that contains soya oil, medium chain triglyceride, olive oil and fish oil {www.tga.gov.au/pdf/auspar/auspar-smoflipid.pdf}, and is used for intravenous nutrition, was used in our experiments after labeling with a 0.05% lipophilic tracer fluorophore, DiD, (DiD307, Invitrogen, Carlsbad, CA). The SMOF lipid emulsion was dried under a rotary evaporator, freeze-dried before mixing well with DiD lipid in an ethanolic solution. The ethanol was finally evaporated and the residual lipid film was rehydrated by addition of sterile Baxter water to make the final concentration to 20% SMOFlipid, followed by harsh vortexing and 30 minutes ultrasonic bath homogenization.
Collection and purification of ApoA-II ApoA-II was purified as described in previous studies [31] [32] [33] . HDLs were ultracentrifugally isolated from pooled samples of normal human plasma (1.063<d<1.21 g/ml)and delipidated. The resulting apoHDL was subjected to chromatography on a Q-Speharose Fast Flow column attached to an Akta FPLC system (GE Healthcare, Chalfont St Giles, Buck, UK). Fractions containing apoA-II were pooled and purity was checked by SDS-PAGE and Coommassie staining, which revealed a single band. The pooled samples were lyophilised, reconstituted with 3 M guanidine hydrochloride/10 mM Tris/0.01% (wt/v) EDTA-Na 2 , and dialysed into endotoxinfree PBS prior to use.
Cell proliferation assay
Cell proliferation was performed in different cell lines and quantified by the crystal violet assay as described in previously [34] , where MTT assay is not suitable in lipid treated cells [35] . Culture medium were removed and stained with 1 μg/ml crystal violet (Sigma Aldrich, St. Louis, MO) dissolved in 25% methanol (v/v) and 75% distilled water (v/v). Bound crystal violet was solubilised with 0.1% sodium-dodecyl-sulphate (SDS) in phosphate buffered saline (PBS). The optical density of each well was determined at the 550 nm wavelength. Results were expressed as relative to control. We found that 1:30 dilution of lipid and 50 μg/ml of ApoA-II were the optimum concentrations at 48 h and this condition was used in the subsequent study.
Immunoblotting
Immunoblot analysis was performed as described previously [1] . Briefly, 4 x10 5 cells of each cell lines seeded in 6 well plates and cells were grown until confluent. Equal amounts of proteins were separated by 10% SDS-PAGE under reducing conditions and transferred to a polyvinylidene difluoride membrane. The primary antibody used was Rabbit anti-SR-B1 (Novus Biologicals, Littleton, USA). Immunoreactivity was detected with the electrochemiluminescence detection system (Amersham Biosciences, Buckinghamshire, UK). Anti-human β-actin antibody was included to normalize against unequal loading.
Confocal microscopy
The uptake of SMOFlipid labeled with DiD was investigated by Confocal microscopy. Briefly, 
Cryo transmission electron microscopy (TEM)
A laboratory-built humidity-controlled vitrification system was used to prepare the samples for Cryo-TEM. Humidity was kept close to 80% for all experiments and ambient temperature was *22°C. A 4 μl aliquot of the sample was pipetted onto a 300 mesh copper grid coated with lacy formvar-carbon film (Pro-SciTech, Thuringowa, Queensland). After 30 s adsorption time, the grid was blotted manually using Whatman 541 filter paper, for between 2 and 10 s. The grid was then plunged into liquid ethane cooled by liquid nitrogen. Frozen grids were stored in liquid nitrogen until examined. The samples were examined using a Gatan 626 cryoholder (Gatan, Pleasanton, CA, USA) and a Tecnai 12 Transmission Electron Microscope (FEI, Eindhoven, The Netherlands) at an operating voltage of 120 kV, equipped with a FEI Eagle 4k × 4k CCD (FEI, Eindhoven, the Netherlands). Samples were viewed at 100 000-150 000 times magnification.
Gel electrophoresis
An aqueous 0.5% m/m agarose gel was prepared and immersed in 1 × TBE (Tris-Borate-EDTA buffer, prepared by diluting 10x stock solutions, pH 9) buffer [36, 37] , run in a horizontal electrophoresis system (Mini-Sub Cell GT, Biorad, electrode spacing 15 cm) for 45 min at 90 V. Gel images were taken with a Carestream MI at wavelength of 650 nm excitation and 700 nm emission. ApoA-II plus lipid was reconstituted by the incubation of 2 μl ApoA-II (2mg/ml) and 2 μl of labeled SMOFlipid (10 mg/ml) at 37°C for 24 hr. Before loading the gel with the sample, each sample was diluted at 1:5 in PBS (pH 7.4) and added 2 μl of 6X loading dye solution (#R0611, Fermentas, Life Science) contain 10mM Tris-HCl (pH 7.6), 0.03% bromophenol blue, 0.03% xylene cyanol FF, 60% glycerol 60mM EDTA buffer. 12 μl of sample was loaded into each well of the gel. All of the experiments were performed at room temperature.
Generation of PDAC patient derived tumour xenograft (PDTX) in nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice
All animal experiments conformed to the guidelines of the Northern Sydney Local Health District (NSLHD) Animal Ethics Committee in this study and housed at Kearns facility, Kolling Institute of Medical Research, the University of Sydney. The protocol was approved by the NSLHD Animal ethics committee (Protocol number 1011-015A). All surgery was performed under anesthesia by using isoflurane with NO 2 and Oxygen (2:1) and all efforts were made to minimize suffering. We have established PDTX model as described by Wong MH and Xue A et al. [38, 39] under the protocol NSLHD HREC-0909-227M. Briefly, male NOD/SCID mice, ages 6 to 8 weeks, were anaesthetized using isoflourane with NO 2 and oxygen (2:1). Small pieces of patient's fresh tumour tissues were xenografted under the subrenal capsule (SRC) in a mouse. At eight weeks post-xenograft, mice were used to investigate the in vivo lipid uptake.
The animals bearing the first generation xenografts (F1) were randomized and distributed into three groups (a) vehicle (saline); (b) lipid (c) lipid plus ApoA-II and injected via tail vein. To homogenize the tumour volumes some of the F1 tumours were passage into other group of mice (F2) and subsequently passage into F3. The animal bearing F3 generation of xenograft tumours were used for validation study. Lipid uptake was measured at different time points by Carestream Molecular Imaging (MI) (Carestream Molecular Imaging, USA). At the end of each experiment organs and tumours were harvested and analysed further.
In vivo image analysis
For in vivo optical imaging, tumor-bearing mice were injected with DiD307 labeled lipid with or without Apo-AII by tail vein injection. Imaging was performed immediately after injection, at 4 h, 24 h, 48 h and 96 h by in-vivo Carestream MI Imaging System. Mice were sacrificed at 48 h after injection, kidney's with tumour, liver, spleen, pancreas, lungs, brain and muscle were harvested and analysed by Carestream MI at wavelength of 650 nm excitation and 700 nm emission.
Histology and immunohistochemistry
Tissue samples were fixed in 10% phosphate buffered formalin and embedded in paraffin. Formalin-fixed, paraffin embedded sections were cut 4-μm thick sections and stained with Mayer's hematoxylin and eosin (H & E). For immunohistochemistry, sections were incubated with anti-ApoA-II (# ab 54796, Abcam, Abcam Inc., MA, USA) (1 in 4000), anti-SR-B1 (#NB 400-104, Novus Biologicals, Littleton, USA) (1 in 4000) and isotype-matched IgG antibodies. Immunodetection was done using the Dako Envision + System-HRP labeled polymer Detection kit (Dako, Carpinteria, CA, USA) according to manufacturers' protocol and counterstained with Mayer's hematoxylin and Scott's bluing solution. After mounting, sections were observed under a light microscope (ECLIPSE 80i; Nikon, Tokyo, Japan).
Statistical analysis
Data were expressed as mean ± standard deviation (S.D.). The statistical significance of group differences were analyzed by paired t-test and analysis of variance (ANOVA) followed by the Bonferroni post hoc test (where appropriate). Statistical significance was accepted at the p < 0.05 level.
Results
ApoA-II's effect on SMOF lipid emulsion
When ApoA-II was added to the opaque lipid emulsion, a phase transition occurred and the emulsified opaque solution transformed to a transparent clear liquid in less than one hour (S1 Fig) . Cryo TEM images of SMOF lipid plus ApoA-II demonstrated that the emulsified particles transformed to unilaminar vesicles (Fig 1B) . More interesting is the small size of these structures, many of which were 10-50 nm in diameter, far smaller than the original particles in the emulsion. This morphological change in structure and size are most likely due to the interaction and integration of the ApoA-AII within the lipid self-assemblies and the transformation to a transparent solution containing mostly small unilamellar vesicles, as demonstrated by Cryo-TEM (Fig 1A and 1B) .
Gel electrophoresis demonstrated that reconstituted ApoA-II plus lipid complexes migrated through the gel as a band while lipid alone still stayed in the well (Fig 1C) , suggesting that ApoA-II altered the lipid emulsion and reduced the particle size allowing migration into the gel. This is consistent with the cryo TEM results (Fig 1A and 1B) .
Confocal microscopy of cancer cells grown in lipid solutions with and without ApoA-II
The uptake of lipid by CFPAC-1 cells (Fig 2A3) , PANC-1 (S2A Fig) and In these experiments ApoA-II was visualized by ApoA-II antibodies which demonstrated that it was localised to cancer cell membranes (Fig 2A and S2 Fig) . While reduced fluorescence intensity was observed in CFPAC-1 cells when cells were pre incubated with the anti SR-B1 blocking antibody (Fig 2A4) . When CFPAC-1 cells were pre incubated with the unlabeled large excess SMOFlipid alone (Fig 2B1) and then incubated with the reconstituted SMOFlipid/ApoA-II/ DiD (Fig 2B2) further uptake of DiD occurred and the ApoA-II antibody stained peripheral components of cells. Thus although preincubation reduced the uptake of SMOFlipid/ApoA-II uptake still occurred through the mechanism of surface attraction to ApoA-II [4, 5] . In the presence of ApoA-II lipid uptake is significantly greater at various concentrations compared with the lipid alone (Fig 2C and 2D) . These results suggest that ApoA-II is attracted to the cell membrane while lipid was transport to the PC cells. This finding is in an agreement with the Fan Y et al. [4] and Silver et al. [5] . Taken together these results support the proposition that lipid nanoparticle may be endocytosed.
SMOFlipid ApoA-II targets PDAC PDTX in vivo
To assess the tumor targeting capacity of lipid plus ApoA-II we employed a PDAC PDTX model in mouse. Lipid/DiD or lipid/DiD/ApoA-II was injected into the tail vein of first generation tumour bearing mice. Whole animal imaging after 48 h revealed lipid uptake in the PDAC xenografts tumours is confined in the lipid plus ApoA-II injected mice compared to lipid alone ( Fig 3A and S3A Fig) but also in the liver, stomach and spleen. This was confirmed on the explanted organs by ex vivo imaging but little lipid was seen in lungs and brain but not seen in normal pancreas (Fig 3B and S3B Fig) . The relative fluorescence intensity was increased by 3.4 fold in targeted cancer tissues, when DiD-lipid/ApoA-II was injected (Fig 3C) 
Scavenger receptor B class type 1 (SR-B1) expression is higher human PDAC
By western blotting, for the first time, we demonstrated that SR-B1 expression was 13.2, 10.6, 3.1 and 2.3 fold higher in PANC-1, MIAPaCa-2, CFPAC-1 and BxPC3 cell lines respectively compared to normal pancreas cell line (HPDE6) (Fig 4A) . Immunohistochemistry (IHC) demonstrated that SR-B1 expression was 3.7 fold greater in PDAC tissue compared to normal pancreas (Fig 4B) . Consistent with Fig 2, we found that ApoA-II expression was higher in tumours when mice were injected with combination of lipid and ApoA-II emulsion (Fig 4C) , while there was no difference in SR-B1 expression in tumours in any groups (Fig 4C) .
ApoA-II enhanced cell proliferation in human cancer cells
Four PC cell lines PANC-1, MIAPaCa-2, CFPAC-1 and BxPC3 grew more rapidly (Fig 4E) when they had lipid and ApoA-II added to their culture medium compared with controls, ApoA-II alone or with lipid alone (except CFPAC-1 cells). Alternatively ApoA-II downregulated normal HPDE6 cells (Fig 4E) . This was most evident at 48 h and implies that the combination of lipid and ApoA-II increased the uptake of lipid and thus energy allowing the PC cells to grow more rapidly. There was a similar effect on human cancer cell lines from lung, breast and prostate at 48 h ( S4 Fig). However, the ApoA-II did not promote the growth of the breast cancer cell line MCF7, which retained the characteristics of differentiation and grows slowly [40] . In addition, preincubation with anti SR-B1 antibody completely reverse lipid plus ApoA-II stimulated cell proliferation in PANC-1, CFPAC-1 and BXPC3 cells and partially but significantly in MIAPaCa-2 cells (Fig 4E) . Interestingly, inhibition of SR-B1 enhanced ApoA-II plus lipid induced downregulation of cell growth in HPDE6 (Fig 4E) . Anti SR-B1 alone at 2.5μg/ml had no significant effect on HPDE6, PANC-1, MIAPaCa-2 and BxPC3 cell lines, while significantly downregulated CFPAC-1 cell growth (Fig 4D) . This may be due to the difference density level of SR-B1 in PANC-1, MIAPaCa-2, BxPC3 and CFPAC-1 cell lines (Fig 4A) .
Discussion
ApoA-II changed the physical structure of SMOF lipid by reducing the size of the lipid particles and inducing the formation of a bilayer membrane nanoparticle-like structure. This is consistent with the known structure and function of ApoA-II in HDL [41] . The combination of ApoA-II and lipid significantly promoted the growth of PC cell lines and cell lines from lung, breast and prostate cancers. In addition, ApoA-II enhance lipid uptake in PANC-1, CFPAC-1, primary tumour cells and in PDXT. The uptake of exogenous lipid emulsion with ApoA-II into PC tumours may utilize the SR-B1 receptor (Fig 2A4) , because it forms a HDL like structure which has a high-affinity to SR-B1 [26] . ApoA-II helps to target lipid to pancreatic cancer in a manner which could be exploited for theranostic purposes.
Apo A-II binds and shrinks a subset of HDL and prolongs its circulation time [12] and inhibits lipoprotein lipase [13] . Pancreatic cancers consume lipids [42] and protein [43] from the extracellular space for the maintenance of anabolic metabolism [44] . Xue A et al found that serum ApoA-II is reduced in PC [1] patient sera which may be due to the increase in consumption by PC. In this study, the fluorescent photomicrographs show the uptake of the SMOFlipid to the cytoplasm of the pancreatic cancer cells when added with ApoA-II. This suggests that ApoA-II helps to target lipid nanoparticles into PC cells. One of the possible explanations is ApoA-II may stablise HDL and increased the binding affinity to its receptors, namely, SR-B1 [15] , which we have demonstrated to be highly expressed in PC cells and PDAC tumours. We have also demonstrated preferential uptake of SMOFlipid when combined with ApoA-II was greater in xenograft compared to normal mouse pancreas. Although this study used human ApoA-II there was some uptake in the liver and spleen, presumably being attracted to murine SR-B1. Nevertheless, SMOFlipid plus ApoA-II also retained selectively in liver and spleen, well known sites for liposome accumulation [45] [46] [47] . This is achieved may be due to the ability of these SMOFlipid plus ApoA-II to circulate with long half-lives (2-4.5 days) (Fig 4, [48, 49] ), enabling them repeated passages through blood vessels feeding growing tumor. On the other hand exogenous ApoA-II may bind and shrink a subset of HDL and prolong its circulation time [12] by decreasing hepatic clearance [12] and increasing the affinity to tumours SR-B1 [15] . In this study, ApoA-II plus lipid enhanced proliferation of PANC-1, MIAPaCa-2, CFPAC-1 and BxPC3 but downregulated normal pancreatic cells. Pancreatic cancers exist in a unique metabolic environment and are extremely dense with interstitial pressures that can exceed 10-times those observed in normal organs like the liver or pancreas [50] . Pancreatic cancer often grows within a fibrotic, abundant, and poorly perfused stroma [51] leading to limited access to nutrients and oxygen. The increased expression of SR-B1 may be an adaptation to facilitate survival and growth by the ability to scavenge lipid and recycled metabolic substrates. This adaptation may be able to be utilized for theranostic purposes to improve the management of patients with pancreatic cancer. 
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